The 20 most recent market catalysts affecting $ACAD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 25, 2026
Corporate Catalyst
Bearish
Impact 55
Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33
Citizens analyst Jason N. Butler maintained a 'Market Outperform' rating on ACADIA Pharmaceuticals but lowered the price target from $36 to $33. This action indicates that while th…
Sep 24, 2026
Corporate Catalyst
Bearish
Impact 85
Acadia Pharma shares are trading lower after the company announced remlifanserin narrowly missed the primary endpoint in its Phase 2 RADIANT study for Alzheimer's disease psychosis.
The failure of remlifanserin to meet its primary endpoint is a significant blow to Acadia Pharma, as this drug was a key pipeline asset with high expectations for treating Alzheime…
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 55
Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $41 Price Target
This 8-K filing discloses that Needham analyst Ami Fadia has reiterated a 'Buy' rating on ACADIA Pharmaceuticals (ACAD) and maintained a $41 price target. This action signals conti…
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 85
Acadia’s Remlifanserin Advances Toward Phase 3 In Alzheimer’s Psychosis Despite Narrow Miss On Primary Endpoint
Acadia Pharmaceuticals announced Phase 2 results for remlifanserin, a drug for Alzheimer's disease psychosis. While it narrowly missed the primary endpoint (p=0.0603), it showed st…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 55
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38
Deutsche Bank analyst David Hoang maintained a 'Buy' rating on ACADIA Pharmaceuticals and raised the price target from $37 to $38. This action signals continued positive sentiment …
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28
Morgan Stanley analyst Jeffrey Hung maintained an 'Equal-Weight' rating on ACADIA Pharmaceuticals while raising the price target from $27 to $28. This action reflects a slightly im…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40
Citigroup analyst Yigal Nochomovitz maintained a 'Buy' rating on ACADIA Pharmaceuticals and raised the price target by a modest $1, from $39 to $40. This action signals continued a…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 75
European Commission Approves Acadia’s DAYBU For Rett Syndrome Patients Aged Five And Older Following Successful Phase 3 LAVENDER Study
This approval is a significant positive for Acadia Pharmaceuticals (ACAD) as it opens up the European market for DAYBU, a drug for a rare neurological disorder. The successful Phas…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49
UBS analyst Ashwani Verma maintained a 'Buy' rating on ACADIA Pharmaceuticals and raised the price target from $45 to $49. This action signals continued confidence in ACADIA's futu…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41
Needham analyst Ami Fadia has maintained a 'Buy' rating on ACADIA Pharmaceuticals and raised the price target from $38 to $41. This action indicates increased confidence from a pro…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39
Citigroup analyst Yigal Nochomovitz maintained a 'Buy' rating on ACADIA Pharmaceuticals and raised the price target from $35 to $39. This action signals increased confidence from a…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $25
Oppenheimer analyst Matthew Hershenhorn reiterated a 'Perform' rating on ACADIA Pharmaceuticals (ACAD) but raised the price target from $23 to $25. This action signals a slightly i…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
ACADIA Pharmaceuticals shares are trading higher after Citizens and RBC Capital raised their respective price targets on the stock.
Analyst price target increases are a significant corporate catalyst, often signaling improved sentiment and potential for stock appreciation. For ACADIA Pharmaceuticals, this sugge…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $37
RBC Capital analyst Brian Abrahams maintained an 'Outperform' rating on ACADIA Pharmaceuticals and slightly raised the price target from $36 to $37. This action signals continued a…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36
Citizens analyst Jason N. Butler maintained a 'Market Outperform' rating on ACADIA Pharmaceuticals and slightly raised the price target from $35 to $36. This action suggests a cont…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
ACADIA Pharmaceuticals Raises FY2026 Sales Guidance from $1.220B-$1.280B to $1.240B-$1.300B vs $1.242B Est
ACADIA Pharmaceuticals (ACAD) has revised its FY2026 sales guidance upwards, moving from $1.220 billion-$1.280 billion to $1.240 billion-$1.300 billion. This is a positive developm…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 92
ACADIA Pharmaceuticals Q2 EPS $0.18 Beats $0.07 Estimate, Sales $307.959M Beat $295.857M Estimate
ACADIA Pharmaceuticals announced Q2 earnings of $0.18 per share, a substantial beat over the $0.07 consensus estimate, and sales of $307.959 million, also exceeding the $295.857 mi…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 55
BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36
BMO Capital analyst Evan David Seigerman maintained an 'Outperform' rating on ACADIA Pharmaceuticals and raised the price target from $34 to $36. This action signals continued anal…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 55
Stifel Maintains Hold on ACADIA Pharmaceuticals, Raises Price Target to $25
This 8-K filing discloses that Stifel analyst Paul Matteis has maintained a 'Hold' rating on ACADIA Pharmaceuticals (ACAD) while slightly increasing its price target from $24 to $2…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 75
Acadia Pharma Secures FDA Fast Track Designation For Remlifanserin For Treatment Of Hallucinations And Delusions Associated With Alzheimer’s Disease Psychosis
Acadia Pharmaceuticals received FDA Fast Track designation for remlifanserin, an investigational drug for Alzheimer's disease psychosis. This is a significant positive development …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.